Commentary
Drug withdrawals from the Canadian market for safety reasons, 1963–2004
Joel Lexchin
CMAJ March 15, 2005 172 (6) 765-767; DOI: https://doi.org/10.1503/cmaj.045021
![Loading Loading](https://www.cmaj.ca/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Respond to this article
Drug withdrawals from the Canadian market for safety reasons, 1963–2004
Joel Lexchin
CMAJ Mar 2005, 172 (6) 765-767; DOI: 10.1503/cmaj.045021
Related Articles
Cited By...
- Cost recovery by Health Canada and drug safety: a time-series analysis
- Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study
- The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics
- Is there still a role for spontaneous reporting of adverse drug reactions?
- Smart Regulation: Will the government's strategy work?